| Sažetak | Objectives: The main aim of this study was to compare serum concentrations of NPY between patients presenting with ST elevation myocardial infarction (STEMI) and patients presenting with non ST elevation myocardial infarction (NSTEMI). In addition, we sought to compare NPY concentrations with various anthropometric, clinical and laboratory data.
Subjects and methods: In this cross-sectional study we enrolled a total of 60 patients with acute myocardial infarction (MI), 30 of which were diagnosed with STEMI, and 30 with NSTEMI. Patients were submitted to thorough clinical examination where anthropometric data was obtained. Subsequently, peripheral blood sample was drawn, and serum Neuropeptide Y (NPY) levels were determined.
Results: NPY levels were significantly higher in patients with NSTEMI compared to patients with STEMI (0.590 (0.550 – 0.650) vs. 0.735 (0.630 – 0.820) ng/mL, P < 0.001). Furthermore, patients with DM had significantly higher NPY serum concentrations (0.640 (0.550 – 0.650) vs. 0.740 (0.720 – 0.754) ng/mL, P=0.046) than patients without DM. The Spearman’s correlation showed that there was no correlation between NPY serum concentrations and neither LVEF (r = 0.073, P=0.609) nor diastolic blood pressure (r = -0.089, P=0.499), respectively, however NPY serum concentrations positively correlated with GRACE score (r = 0.293; P=0.023). Finally, NPY serum concentrations positively correlated with urea (r = 0.318, P=0.013) and creatinine (r = 0.298, P=0.020) levels, and negatively with estimated glomerular filtration rate (r = -0.374, P=0.003).
Conclusions: We concluded that NPY concentrations are significantly higher in patients with NSTEMI in comparison to patients with STEMI, and that NPY concentrations in patients with acute MI are significantly higher among patients with diabetes but with no difference between hypertensive and non-hypertensive patients. In addition, NPY concentrations correlate with the risk of mortality and renal function parameters in patients with MI. |
| Sažetak (hrvatski) | Cilj: Glavni cilj ovog istraživanja bio je usporediti serumske koncentracije neuropeptida Y (NPY) među bolesnicima s infarktom miokarda sa ST elevacijom (engl. ST elevation myocardial infarction, STEMI) i infarkta miokarda bez ST elevacije (engl. non ST elevation myocardial infarction, NSTEMI). Također, usporedili smo razine NPY s raznim kliničkim i laboratorijskim parametrima.
Materijali i metode:. U ovu presječnu studiju uključili smo 30 bolesnika sa STEMI-jem i 30 s NSTEMI-jem. Bolesnici su podvrgnuti detaljnom kliničkom pregledu gdje su uzeti i antropometrijski podaci. Konačno iz uzoraka krvi smo analizirali razne laboratorijske parametre uključujući NPY.
Rezultati: Serumske razine NPY-a su bile značajno veće u bolesnika s NSTEMI-jem u usporedbi s bolesnicima s STEMI-jem (0,590 (0,550 – 0,650) vs. 0,735 (0,630 – 0,820) ng/mL, P < 0,001). Nadalje, bolesnici koji boluju od šećerne bolesti imali značajno veće koncentracije NPY-a od ispitanika koji ne boluju od iste (0,640 (0,550 – 0,650) vs. 0,740 (0,720 – 0,754) ng/mL, P=0,046). Spearmanova korelacijska analiza pokazala je da serumske koncentracije NPY-a ne koreliraju s ejekcijskom frakcijom (r = 0,073, P=0,609) ni s vrijednostima dijastoličkog tlaka (r = -0,089, P=0,499), ali koreliraju s GRACE zbirom (r = 0,293; P=0,023). Konačno, serumske koncentracije NPY-a pozitivno su korelirale s urejom (r = 0,318, P=0,013) i kreatininom (r = 0,298, P=0,020), a negativno s procijenjenom glomerularnom filtracijom (r = -0,374, P=0,003).
Zaključci: Utvrdili smo značajno veće koncentracije NPY u bolesnika s NSTEMI-jem u odnosu na bolesnike sa STEMI-jem. Uz to, demonstrirali smo da su koncentracije značajno veće u dijabetičara u odnosu na ne-dijabetičare, te da nema značajne razlike između hipertoničara i ispitanika koji nisu bolovali od hipertenzije. Konačno, pronašli smo značajnu korelaciju razina NPY-a s GRACE zbirom i markerima bubrežne funkcije. |
